RNA, U6 small nuclear 912, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-912P profile across patient tissues and cancer cell-line models. RNU6-912P expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU6-912P is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, RNU6-912P RNA expression shows 6,130 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, PRAD, and STAD as cancer lineages where RNU6-912P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-912P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-912P survival associations across molecular data types. RNU6-912P RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-912P RNA expression–survival associations across cancer types. High RNU6-912P expression shows unfavorable associations in LIHC, KIRP, COAD and READ, but favorable associations in ESCA and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU6-912P RNA expression.
This table summarizes RNU6-912P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-912P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-912P shows higher tumor expression in PRAD. The PRAD box plot shows higher RNU6-912P RNA expression in tumor versus normal tissue (log2 FC = +0.057, t-test p = .022).
This table shows molecular features associated with RNU6-912P in patient tissues and cancer cell lines. In patient samples, RNU6-912P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
